New research reveals PD-L1 expression enhances survival in advanced ovarian cancer, linking it to homologous recombination deficiency and treatment personalization.

Multiple Instance Learning-based Prediction of PD-L1 Expression from H&E-stained Histopathological Images in Breast Cancer This project is based on the Multiple Instance Learning (MIL) method and ...

TPS (Tumor Proportion Score) serves as a crucial indicator to determine the eligibility of cancer patients for PD-L1 immunohistochemistry (IHC) treatment. In clinical practice, pathologists assess TPS ...

Synopsis PD-L1 is a key immune checkpoint and largely affects the response of patients to immunotherapy. This study identifies ependymin-related protein 1 (EPDR1) as a potent regulator of PD-L1 ...

Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ROS1 rearrangements.

Here, we reported that PD-L1 is a unique target for UFMylation. Decreased expression of UFL1 reduces the UFMylation of PD-L1, which stabilizes PD-L1 and imparts immune evasion. A covalent inhibitor of ...

Studies have identified the indispensable role of PD-L1 expression on such immune cells for the therapeutic efficacy of PD-1/PD-L1 blockade therapy (9, 10). As such, PD-L1 expression on tumor cells as ...

PURPOSEIn many cancers, the expression of immunomodulatory ligands leads to immunoevasion, as exemplified by the interaction of PD-L1 with PD-1 on tumor-infiltrating lymphocytes. Profound advances in ...

Patients with PD-L1 expression at initial transurethral resection for bladder cancer were more likely to harbor invasive disease, according to investigators. PD-L1 expression may assist in ...

PD-L1 expression in tumors is currently used as a biomarker to orient therapeutic decisions; nevertheless, our knowledge about the regulation of PD-L1 expression is limited. The present review ...